Navigation Links
Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
Date:1/12/2009

- Albuferon(R) for hepatitis C, LymphoStat-B(R) for lupus and ABthrax(R) for inhalation anthrax all progressing rapidly toward commercialization -

- GSK Phase 3 trial of darapladib underway in chronic coronary heart disease -

- HGS provides 2009 financial guidance; expects less than $25 million net cash burn -

ROCKVILLE, Md., Jan. 12 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) will announce its priority goals for 2009 and report on the Company's progress toward commercialization during a presentation by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 27th Annual JPMorgan Healthcare Conference in San Francisco on Wednesday, January 14.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

"2009 will be a pivotal year for HGS," said Mr. Watkins. "In December 2008, we reported the positive results of Albuferon's first Phase 3 trial in chronic hepatitis C. We will have the results of Albuferon's second Phase 3 trial in March. Assuming the second trial is also successful, we expect that global marketing applications will be filed in fall 2009. We will have the results of our two Phase 3 trials of LymphoStat-B in systemic lupus erythematosus (SLE) in July and November, respectively, and expect to file marketing applications in the first half of 2010 if LymphoStat-B is successful in these studies. We are confident that we will deliver 20,000 doses of ABthrax to the U.S. Strategic National Stockpile early in the year and will receive at least $150 million in revenues in 2009. We also expect major financial progress in 2009, with revenues of more than $250 million and net cash burn of less than $25 million."

Dur
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical ... purification technology to help fight deadly inflammation in ... worldwide, today announced the appointment of Dr. ... its Senior Vice President of Clinical Development, effective ... Di Russo is an accomplished pediatric cardiothoracic ...
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... of the "Investment Analysis of the US ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... US medical device sector identifies the key trends ... capital investments, and mergers and acquisitions. ...
(Date:12/22/2014)... 2014  Mark Farrah Associates (MFA), www.markfarrah.com ... of the 2015 marketplace exchange projections and insights ... According to a recent ASPE (Office of ... of Health and Human Services) report, an estimated ... plans through the Marketplace as of October 2014 ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5Investment Analysis of the US Medical Device Sector 2Insights into the Marketplace and Individual Market Growth 2
... , , , DURHAM, N.C., Dec. 14 ... expansion of the company,s board of directors with the addition ... Dr. Blanck is chairman of Martin, Blanck & Associates, a ... With his addition, the company board now has nine members. ...
... , DOVER, Del., Dec. 14 Ohr Pharmaceutical Inc. (OTC ... & Caron Inc, headquartered in Irvine, CA, with offices ... for investor relations and corporate communications. Ohr Pharmaceutical ... advanced drugs for underserved therapeutic needs. The Company acquired ...
Cached Medicine Technology:Oxygen Biotherapeutics, Inc. Expands Board of Directors 2Ohr Pharmaceutical Selects Allen & Caron for Investor Relations, Corporate Communications 2Ohr Pharmaceutical Selects Allen & Caron for Investor Relations, Corporate Communications 3
(Date:12/25/2014)... Parker & Sons, Inc. an industry leader when ... regarding heating, cooling and plumbing services in the greater ... “Queen of Clean” for impressive contractor services in Arizona. ... the years for providing outstanding quality customer service and ... for both homeowners and businesses. Linda Cobb, known as ...
(Date:12/24/2014)... Over 700 toys, that’s what AlignLife ... is 700 smiling little faces this holiday that might ... in monetary donations was given to the various charities ... they incur through the year. Some of the charities ... Haven , Shrine's Children's Hospitals, Toys for Tots and ...
(Date:12/24/2014)... TX (PRWEB) December 24, 2014 Connie ... specialist and functional medicine advocate with 30 years of ... trial to evaluate the health benefits of dietary detoxification. ... with new participants following excellent results from test patients ... When asked to explain her interest in conducting the ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Risperdal lawsuit ... a mass tort litigation currently underway in Pennsylvania’s Philadelphia ... As of December 24, 2014, court documents indicate that ... behalf of individuals who developed gynecomastia (male breast growth) ... from the Court indicates that this represents an increase ...
(Date:12/24/2014)... 24, 2014 Dr. Vu Ho, a ... of his practice and med-spa with the addition of ... list of cosmetic treatments and services. , “Silk Peel ... skin,” says Dr. Ho. “As a result it can ... wrinkles, sun spots, discolorations or blemishes.” , Similar to ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2
... Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics ... covers the use of endonuclease-based reporting in PCR and other ... filed a claim in opposition to this patent which was ... Munich on May 28. , , The ...
... ... Leading Healthcare Cost-Management Company , ... Westminster, Colo. (PRWEB) June 16, 2009 -- Silver Creek ... integration and governance announced today that their DataLens™ System was selected by Broadlane®, ...
... SAN FRANCISCO, California, June 16, Autonomy Corporation plc (LSE: ... the enterprise, today announced,that the Greater Cincinnati Behavioral Health ... capture, route, store and manage,its patients records. With Autonomy, ... all of their patients, records online, rather than having ...
... ... better decisions , ... Indianapolis, Indiana (Vocus) June 16, 2009 -- United Benefit Advisors, LLC (UBA), one of ... 2009 UBA Employer Benefit Perspectives survey (video) , which delineates employers, positions ...
... Mike Ramsey, a ... explains the process in his book "Stop Sweating and Start Living." , ... (PRWEB) June 16, 2009 -- If you suffer ... save you money and frustration., , , , ,Written by Mike Ramsey, who first started ...
... ... Manhattan LASIK Center, even though the iLASIK™ Procedure is not without risk, wearing contacts has ... of magnitude more common when compared to the iLASIK procedure. , ... New York, NY (PRWEB) June 16, 2009 -- Board ...
Cached Medicine News:Health News:Enigma Diagnostics Announces Patent On Real-Time Monitoring of Amplification Reactions Upheld In Entirety Following Opposition From BD at European Patent Office 2Health News:Broadlane Selects Silver Creek Systems To Accelerate Core Business Analysis And New Client Services 2Health News:Broadlane Selects Silver Creek Systems To Accelerate Core Business Analysis And New Client Services 3Health News:Greater Cincinnati Behavioral Health Services Standardizes on Autonomy's Meaning-Based Technologies 2Health News:Greater Cincinnati Behavioral Health Services Standardizes on Autonomy's Meaning-Based Technologies 3Health News:Employees Increasingly Accept and Understand Reductions in Health Plan Benefits and Premium-Cost Sharing 2Health News:Employees Increasingly Accept and Understand Reductions in Health Plan Benefits and Premium-Cost Sharing 3Health News:Man Discovers Cure for Excessive Sweating 2Health News:Kevin Niksarli, M.D. of Manhattan Lasik Center Reviews Pros and Cons of Contact Lenses vs. iLASIK at an International Meeting on 7/1/2009 2
Thin, smooth bottom edge for gently scraping away the epithelium, Spatula tip & top are slightly sharpened to facilitate more aggressive scraping...
Used after ablation to wash away particulate from anterior & posterior sides of flap & stromal bed. Conforms to the corneal flap. .0mm extension with a 11.0mm radius, Angled tip....
Smaller diameter wire probes & olive shape tips provide easier insertion through the lacrimal sac, 35cm (14 in) long, ID- .30mm (.012in); OD- .64mm (.025 in). S.S. Probes: .40mm x 11cm (27 G x 4 1/4...
...
Medicine Products: